Core Viewpoint - The stock price of HeFu China (603122.SH) has significantly deviated from its fundamentals, raising concerns about potential risks for investors, with a cumulative increase of 291.92% over a specific period, leading to possible suspension of trading for further investigation [2][5][6] Group 1: Stock Performance - As of November 20, the stock price closed at 26.18 yuan per share, marking a historical peak with a turnover rate of 24.46% [5] - The stock has experienced 13 trading days of closing at the涨停 price and has encountered multiple instances of abnormal price fluctuations [2][5] - The recent surge in stock price is viewed as a result of overheated market sentiment and irrational speculation, significantly outpacing the industry and Shanghai Composite Index [5] Group 2: Financial Performance - HeFu China's Q3 report indicates a revenue of 549 million yuan for the first three quarters, a year-on-year decline of 22.80%, with a net loss of 12.39 million yuan, down 146.65% [6] - The third quarter alone saw revenue drop to 181 million yuan, a 21.27% decrease, with a net loss of 5.05 million yuan compared to a profit of 4.03 million yuan in the same period last year [6] - The company has faced a continuous decline in performance since its peak in 2022, with revenues projected to decrease from 1.28 billion yuan in 2022 to 939 million yuan in 2024, and net profit shrinking from 82.72 million yuan to 27.57 million yuan [6] Group 3: Business Challenges - The decline in performance is attributed to adjustments in medical industry policies, leading to reduced procurement prices and order volumes from hospital clients, which have adversely affected sales and profits [6] - Despite implementing various cost control measures, the company has not been able to fully offset the revenue decline in the short term, indicating ongoing pressure on operational performance [6]

辑 11月20日，合富中国复牌，开盘后直线拉升，盘中再度涨停，走出15天13板行情。截至收盘，该股报 26.18元/股，成交额超24亿元。 编 11月20日晚间，合富中国公告，公司股价累计涨幅已严重偏离基本面，投资者参与交易可能面临较大风 险。如公司股价进一步异常上涨，公司可能申请停牌核查。自2025年10月28日至2025年11月20日，公司 股票有十三个交易日以涨停价收盘，并5次触及股价异常波动、3次触及严重异常波动情形，期间累计涨 幅高达291.92%。 公告提示，股价短期内连续上涨，存在市场情绪过热、非理性炒作风险，已明显高于同期行业及上证指 数涨幅，且严重显著偏离公司基本面，随时存在快速下跌风险。本次股价连续上涨期间，公司股票流通 换手率亦出现较大波动情形，击鼓传花效应明显。 | 钉钉 ...

合富中国（603122）(603122.SH)发布公告，公司股价累计涨幅已严重偏离基本面，投资者参与交易可 能面临较大风险。如公司股价进一步异常上涨，公司可能申请停牌核查。自2025年10月28日至2025年11 月20日，公司股票有十三个交易日以涨停价收盘，并5次触及股价异常波动、3次触及严重异常波动情 形，期间累计涨幅高达291.92%。截至11月20日收盘，公司股价为26.18元/股，处于历史最高位，换手 率达24.46%。股价短期内连续上涨，存在市场情绪过热、非理性炒作风险，已明显高于同期行业及上 证指数涨幅，且严重显著偏离公司基本面，随时存在快速下跌风险。 ...

北京商报讯（记者 丁宁）11月20日，复牌首日的合富中国（603122）再度涨停收盘。盘后，合富中国 发布公告称，如公司股价进一步异常上涨，公司可能申请停牌核查。 公告显示，自10月28日至11月20日，公司股票有十三个交易日以涨停价收盘，并5次触及股价异常波 动、3次触及严重异常波动情形，期间累计涨幅高达291.92%。截至11月20日收盘，公司股价为26.18元/ 股，处于历史最高位，换手率达24.46%。股价短期内连续上涨，存在市场情绪过热、非理性炒作风 险，已明显高于同期行业及上证指数涨幅，且严重显著偏离公司基本面，随时存在快速下跌风险。 ...

智通财经APP讯，合富中国(603122.SH)发布公告，公司股价累计涨幅已严重偏离基本面，投资者参与 交易可能面临较大风险。如公司股价进一步异常上涨，公司可能申请停牌核查。自2025年10月28日至 2025年11月20日，公司股票有十三个交易日以涨停价收盘，并5次触及股价异常波动、3次触及严重异常 波动情形，期间累计涨幅高达291.92%。截至11月20日收盘，公司股价为26.18元/股，处于历史最高 位，换手率达24.46%。股价短期内连续上涨，存在市场情绪过热、非理性炒作风险，已明显高于同期 行业及上证指数涨幅，且严重显著偏离公司基本面，随时存在快速下跌风险。 ...

Core Viewpoint - The company, HeFu China (603122.SH), has announced that its stock price has significantly deviated from its fundamentals, indicating potential risks for investors participating in trading [1] Group 1: Stock Performance - From October 28, 2025, to November 20, 2025, the company's stock experienced a cumulative increase of 291.92%, with thirteen trading days closing at the limit-up price and five instances of abnormal price fluctuations [1] - As of November 20, 2025, the stock price closed at 26.18 yuan per share, marking a historical peak, with a turnover rate of 24.46% [1] Group 2: Market Sentiment and Risks - The recent continuous rise in stock price suggests an overheated market sentiment and risks of irrational speculation, which is significantly higher than the growth rates of the industry and the Shanghai Composite Index during the same period [1] - The company has issued multiple announcements regarding abnormal trading fluctuations and risk warnings between October 30, 2025, and November 14, 2025, and conducted a stock suspension review from November 17 to November 19, 2025 [1]

合富中国公告，公司股价累计涨幅已严重偏离基本面，投资者参与交易可能面临较大风险。如公司股价 进一步异常上涨，公司可能申请停牌核查。自2025年10月28日至2025年11月20日，公司股票有十三个交 易日以涨停价收盘，并5次触及股价异常波动、3次触及严重异常波动情形，期间累计涨幅高达 291.92%。截至11月20日收盘，公司股价为26.18元/股，处于历史最高位，换手率达24.46%。股价短期 内连续上涨，存在市场情绪过热、非理性炒作风险，已明显高于同期行业及上证指数涨幅，且严重显著 偏离公司基本面，随时存在快速下跌风险。 ...

Core Viewpoint - The stock of ST Zhongdi experienced an abnormal price fluctuation with a cumulative increase of 18.07% over three consecutive trading days from November 18 to 20, 2025, despite poor financial performance and a change in control of the company [1] Financial Performance - For the first three quarters of 2025, the company reported revenue of 134.71 million yuan, a year-on-year decrease of 52.64% [1] - The total profit for the same period was -151.07 million yuan, reflecting a year-on-year decline of 41.83% [1] - The net profit after deducting non-recurring items was -132.35 million yuan, down 34.12% year-on-year [1] Change in Control - The controlling shareholder has changed to Shenzhen Tianwei Investment Partnership (Limited Partnership), with the actual controllers now being Men Hongda and Zhang Wei [1] Risk Warnings - The company has highlighted several risks including the divergence of stock price from fundamentals, poor performance, debt defaults, and legal issues related to guarantees, urging investors to make cautious decisions [1]

Core Viewpoint - The stock of HeFu China (603122) experienced significant volatility, with a cumulative increase of 256.29% over a period of 14 trading days, leading to a temporary suspension of trading for verification due to abnormal price fluctuations [1][2] Group 1: Stock Performance and Trading Suspension - HeFu China announced the completion of a trading suspension verification, with the stock set to resume trading on November 20, 2025 [1] - The stock hit the daily limit up on 12 out of 14 trading days, with five instances of abnormal fluctuations and three instances of severe fluctuations [1] - The company’s stock price is currently significantly higher than its operational performance and industry conditions, indicating a potential disconnect [1][2] Group 2: Financial Performance and Valuation - As of November 14, 2025, HeFu China's static price-to-earnings (P/E) ratio was 343.67, compared to the industry average of 30.94, suggesting a bubble in the stock price [2] - The company reported a net loss of 5.048 million yuan in Q3 2025, a year-on-year decline of 225.26%, attributed to changes in the macroeconomic environment and price reductions in the medical industry [2] - Despite implementing cost control measures, the company faces pressure on its short-term operating performance due to declining sales revenue and profit levels [2]

Group 1 - The company announced the completion of a stock suspension review, with shares resuming trading on November 20, 2025 [2] - During the period from October 28 to November 14, 2025, the company's stock experienced a significant increase, closing at the daily limit on 12 out of 14 trading days, with a cumulative rise of 256.29% [2] - The company reported that its current stock price significantly deviates from its operating performance and industry conditions, leading to a temporary suspension of trading [2] Group 2 - The company's current price-to-earnings (P/E) ratio is 343.67, which is substantially higher than the industry average P/E ratio of 30.94, indicating a potential bubble in the stock price [3] - The company is currently operating at a loss, with a net profit of -5.048 million yuan for Q3 2025, a year-on-year decline of 225.26%, primarily due to changes in the domestic macroeconomic environment and price reductions in the medical industry [3] - Despite implementing cost control measures, the company faces pressure on its short-term operating performance due to a decline in sales revenue and profit levels [3]